Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study

Annals of Oncology

Volumn 19, Issue 2, 2008, Pages 292-298

  von Minckwitz, G ^a   Kummel S ^b,c   du Bois, A ^d   Eiermann, W ^e   Eidtmann, H ^f   Gerber, B ^g   Hilfrich, J ^h   Huober, J ⁱ   Costa, S D ^j   Jackisch, C ^k   Grasshoff, S T ^l   Vescia, S ^a   Skacel, T ^m,n   Loibl, S ^a   Mehta, K M ^a   Kaufmann, M ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d DR HORST SCHMIDT KLINIKEN   (Germany)

^e Frauenklinik vom Roten Kreuz   (Germany)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^g ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^h Henriettenstift Frauenklinik   (Germany)

ⁱ UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^j UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^k Klinik für Gynäkologie und Geburtshilfe   (Germany)

^l Frauenklinik   (Germany)

^m AMGEN INC   (United States)

ⁿ UNIVERSITY HOSPITAL BRNO   (Czech Republic)

more..

Author keywords

Breast cancer; Ciprofloxacin; Docetaxel; Febrile neutropenia; Granulocyte colony stimulating factor; Primary prophylaxis

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT; TAC PROTOCOL; TAXOID; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DYSPHAGIA; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; LEUKOPENIA; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPENIC ENTEROCOLITIS; PRIORITY JOURNAL; SEPSIS; STOMATITIS; THROMBOCYTOPENIA; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PILOT STUDY; PROBABILITY; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FILGRASTIM; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEUTROPENIA; PILOT PROJECTS; PROBABILITY; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 38849085135     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm438     Document Type: Article

References (23)

1. Perez EA. TAC - a new standard in adjuvant therapy for breast cancer? N. Engl. J. Med. 2005; 352: 2346-2348.
2. Martin M, Pienkowski T, Mackey J et al. Adjuvant docetaxel for node-positive breast cancer. N. Engl. J. Med. 2005; 352: 2302-2313.
3. von Minckwitz G, Blohmer JU, Raab G et al. In vivo chemosensitivity adapted preoperative chemotherapy in patients with early-stage breast cancer: The GEPARTRIO pilot study. Ann. Oncol. 2005; 16: 56-63.
4. Martin M, Lluch A, Segui MA et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC) impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann. Oncol. 2006; 17: 1205-1212.
5. Ozer H, Armitage JO, Bennett CL et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J. Clin. Oncol. 2000; 18: 3558-3585.
6. National Cancer Institute. Common Toxicity Criteria Version 2.1. http://ctep.cancer.gov/reporting/ctc.html (24 August 2007 date last accessed).
7. Hughes WT, Armstrong D, Bodey GP et al. 2002 guidelines foe the use of antimicrobial agents in neutropenic patients with cancer. Clin. Infect. Dis. 2002; 34: 730-751.
8. Gafter-Gvili A, Fraser A, Paul M, Leibuvici L. Meta-analysis: Antibiotic prophylaxis reduces mortality in neutropenic patients. Ann. Intern. Med. 2005; 142: 979-995.
9. Timmer-Bonte JN, de Boo TM, Smit HJ et al. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: A Dutch randomized phase III study. J. Clin. Oncol. 2005; 23: 7974-7984.
10. Vogel CL, Wojtukiewicz MZ, Carroll RR et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebo-controlled phase III study. J. Clin. Oncol. 2005; 23: 1178-1184.
11. Smith TJ, Khatcheressian J, Lyman GH et al. 2006 update of recommendations for the use of white blood cell growth factors: An evidenoe-based clinical practice guideline. J. Clin. Oncol. 2006; 24: 3187-3205.
12. Aapro MS Cameron DA, Pettengell R et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours, Eur. J. Cancer 2006; 42: 2433-2453.
13. National Comprehensive Cancer Network Practice Guidelines in Oncology V.2,2005. Myeloid Growth Factors in Cancer Treatment 2005: http://www.nccn.org/professionals/physician_gls/PDF/ myeloid_growth.pdf (November 2006, date last accessed).
14. Amgen: Neupogen_tm. Summary of Product Characteristics. 2002.
15. Weycker D, Hackett J, Edelsberg JS et al. Are shorter courses at filgrastim prophylaxis associated with increased risk of hospitalization? Ann. Pharmacother. 2006; 40: 402-407.
16. Scott SD, Chrischilles EA, Link BK et al. Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy. J. Manag. Care Pharm. 2003; 9: 15-21.
17. Meza LA, Charu V, Campos L et al. Pegfilgrastim and filgrastim patterns of use in community oncology practices: result of the ACCEPT study, J Clin Oncol 2005; 23: (Abstr 6113).
18. von Minckwitz G, Raab G, Caputo A et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J. Clin. Oncol. 2005; 23: 2676-2685.
19. Green MD, Koelbl H, Baselga J et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann. Oncol. 2003; 14: 29-35.
20. Holmes FA, Jones SE, O'Shaughnessy J et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann. Oncol. 2002; 13: 903-909.
21. Koumakis G, Vassilomanolakis N, Barbounis V et al. Optimal timing (preemptive versus supportive) of granulocyte colony stimulating factor administration following high-dose cyclophosphamide. Oncology 1999; 56: 28-35.
22. Molineux G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr. Pharm. Des. 2004; 10: 1235-1244.
23. Siena S, Piccart MJ, Holmes FA et al. A combined analysis of two-pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily filgrastim in patients with stage II-IV breast cancer. Oncol. Rep. 2003; 10: 715-724.